GSK-ARA102198



A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis
rosiglitazone
ARA102198
NCT00379600
Arthritis, Rheumatoid
Phase 2
 
September 2013